Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Not Recruiting

Trial ID: NCT00185757

Purpose

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

Official Title

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Stanford Investigator(s)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant

   - eligible for DLI

   - no evidence of GVHD

   - stable immunosuppressive regimen

   - adequate renal and liver function Exclusion Criteria:- CML patients who have not
   received DLI, active infections

Intervention(s):

drug: Cytokine Induced Killer Cells

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts

Receive email alerts when trials open to patients.